NZ517961A - Bicyclic amino acids as pharmaceutical agents - Google Patents
Bicyclic amino acids as pharmaceutical agentsInfo
- Publication number
- NZ517961A NZ517961A NZ517961A NZ51796100A NZ517961A NZ 517961 A NZ517961 A NZ 517961A NZ 517961 A NZ517961 A NZ 517961A NZ 51796100 A NZ51796100 A NZ 51796100A NZ 517961 A NZ517961 A NZ 517961A
- Authority
- NZ
- New Zealand
- Prior art keywords
- amino acids
- disorders
- pharmaceutical agents
- compounds
- bicyclic amino
- Prior art date
Links
- -1 Bicyclic amino acids Chemical class 0.000 title abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006083 Hypokinesia Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000002173 dizziness Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000003483 hypokinetic effect Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
- C07C2602/28—Hydrogenated naphthalenes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16072599P | 1999-10-20 | 1999-10-20 | |
| PCT/US2000/028687 WO2001028978A1 (en) | 1999-10-20 | 2000-10-17 | Bicyclic amino acids as pharmaceutical agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ517961A true NZ517961A (en) | 2002-12-20 |
Family
ID=22578159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ517961A NZ517961A (en) | 1999-10-20 | 2000-10-17 | Bicyclic amino acids as pharmaceutical agents |
Country Status (50)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7164034B2 (en) | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
| NZ522480A (en) * | 2000-06-26 | 2005-06-24 | Warner Lambert Co | Gabapentin analogues for sleep disorders |
| US6620829B2 (en) | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
| EP1226820A1 (en) | 2001-01-26 | 2002-07-31 | Warner-Lambert Company | Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders |
| CA2444053C (en) * | 2001-04-19 | 2008-06-17 | Warner-Lambert Company Llc | Fused bicyclic or tricyclic amino acids |
| GB2375109A (en) * | 2001-05-04 | 2002-11-06 | Warner Lambert Co | Process for preparing bicyclic amino acid |
| GB2375108A (en) * | 2001-05-04 | 2002-11-06 | Warner Lambert Co | Production of a bicycloheptanone |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| AU2002310409C1 (en) * | 2001-06-11 | 2008-04-17 | Xenoport, Inc. | Orally administered dosage forms of GABA analog prodrugs having reduced toxicity |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| PL371944A1 (en) | 2002-01-31 | 2005-07-11 | Warner-Lambert Company Llc | Alpha 2 delta ligands to treat tinnitus |
| RU2286151C2 (ru) * | 2002-02-22 | 2006-10-27 | Уорнер-Ламберт Компани Ллс | Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2 |
| JP2005534678A (ja) * | 2002-06-27 | 2005-11-17 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 注意欠陥多動性障害の治療方法 |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
| BR0313432A (pt) * | 2002-08-15 | 2005-07-12 | Pfizer | Uso terapêutico de aminoácidos bicìclicos ou tricìclicos fundidos |
| GB0223072D0 (en) | 2002-10-04 | 2002-11-13 | Pfizer Ltd | Cyclic nitromethyl acetic acid derivatives |
| US7018818B2 (en) | 2002-10-04 | 2006-03-28 | Pfizer Inc. | Intermediates in the preparation of therapeutic fused bicyclic amino acids |
| AU2003297927A1 (en) | 2002-12-11 | 2004-06-30 | Xenoport, Inc. | Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof |
| PT1572173E (pt) | 2002-12-13 | 2010-05-10 | Warner Lambert Co | Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| EP2172197A1 (en) | 2002-12-13 | 2010-04-07 | Warner-Lambert Company LLC | Octanoic acid derivative to treat fibromyalgia and other pains |
| ATE449633T1 (de) | 2003-09-12 | 2009-12-15 | Pfizer | Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern |
| WO2006092692A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| AR061728A1 (es) * | 2006-06-30 | 2008-09-17 | Pfizer Prod Inc | Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1 |
| CN102058885B (zh) | 2006-12-22 | 2013-04-10 | 瑞蔻达蒂爱尔兰有限公司 | 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗 |
| KR101335784B1 (ko) | 2007-09-28 | 2013-12-05 | 다이이찌 산쿄 가부시키가이샤 | 2 고리성 γ-아미노산 유도체 |
| WO2010110361A1 (ja) * | 2009-03-26 | 2010-09-30 | 第一三共株式会社 | 二環性γ－アミノ酸誘導体の製造方法 |
| BR112013031360B1 (pt) | 2011-06-08 | 2022-01-25 | Daiichi Sankyo Company, Limited | Método para produzir um composto |
| ES2649968T3 (es) | 2011-06-08 | 2018-01-16 | Daiichi Sankyo Company, Limited | Procedimiento de producción de un compuesto bicíclico vía transposición de Claisen |
| HUE040225T2 (hu) | 2011-12-15 | 2019-02-28 | Daiichi Sankyo Co Ltd | Eljárás biciklikus vegyület optikai elválasztására aszimmetrikus katalizátort felhasználva |
| HUE033397T2 (en) | 2012-04-10 | 2017-12-28 | Daiichi Sankyo Co Ltd | A method for the optical separation of bicyclic compounds by an enzyme |
| US9066853B2 (en) | 2013-01-15 | 2015-06-30 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
| TWI635071B (zh) | 2013-07-08 | 2018-09-11 | 第一三共股份有限公司 | 光學活性二環γ－胺基酸衍生物及其製造方法 |
| WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
| CN113045410A (zh) * | 2021-03-29 | 2021-06-29 | 华东理工大学 | 一种双环降二萜类化合物及其合成基因及制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3641129A (en) | 1969-06-17 | 1972-02-08 | Merck & Co Inc | Antifibrinolytic compounds |
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4087544A (en) * | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| ATE323067T1 (de) | 1997-10-27 | 2006-04-15 | Warner Lambert Co | Zyklische aminosäuren und deren derivate als arzneimittel |
-
2000
- 2000-10-05 HN HN2000000224A patent/HN2000000224A/es unknown
- 2000-10-06 SV SV2000000188A patent/SV2001000188A/es not_active Application Discontinuation
- 2000-10-17 HR HRP20040709 patent/HRP20040709A2/xx not_active Application Discontinuation
- 2000-10-17 IL IL14914300A patent/IL149143A0/xx not_active IP Right Cessation
- 2000-10-17 HU HU0203325A patent/HUP0203325A3/hu unknown
- 2000-10-17 DZ DZ003197A patent/DZ3197A1/xx active
- 2000-10-17 TR TR2002/01094T patent/TR200201094T2/xx unknown
- 2000-10-17 EP EP00972226A patent/EP1226110B1/en not_active Expired - Lifetime
- 2000-10-17 ES ES04027485T patent/ES2282785T3/es not_active Expired - Lifetime
- 2000-10-17 DE DE60019628T patent/DE60019628T2/de not_active Expired - Lifetime
- 2000-10-17 YU YU29302A patent/YU29302A/sh unknown
- 2000-10-17 AT AT04027485T patent/ATE358116T1/de not_active IP Right Cessation
- 2000-10-17 KR KR1020027005036A patent/KR100593349B1/ko not_active Expired - Fee Related
- 2000-10-17 CZ CZ20021310A patent/CZ295960B6/cs not_active IP Right Cessation
- 2000-10-17 KR KR1020067002249A patent/KR100566462B1/ko not_active Expired - Fee Related
- 2000-10-17 GE GE4783A patent/GEP20043297B/en unknown
- 2000-10-17 CA CA2386297A patent/CA2386297C/en not_active Expired - Fee Related
- 2000-10-17 HR HR20020428A patent/HRP20020428B1/xx not_active IP Right Cessation
- 2000-10-17 ES ES00972226T patent/ES2237464T3/es not_active Expired - Lifetime
- 2000-10-17 PT PT00972226T patent/PT1226110E/pt unknown
- 2000-10-17 UA UA2002032434A patent/UA72931C2/uk unknown
- 2000-10-17 DE DE60034157T patent/DE60034157T2/de not_active Expired - Lifetime
- 2000-10-17 IL IL16406000A patent/IL164060A0/xx unknown
- 2000-10-17 WO PCT/US2000/028687 patent/WO2001028978A1/en not_active Ceased
- 2000-10-17 PL PL00354607A patent/PL354607A1/xx not_active Application Discontinuation
- 2000-10-17 NZ NZ517961A patent/NZ517961A/xx unknown
- 2000-10-17 SI SI200030670T patent/SI1226110T1/xx unknown
- 2000-10-17 BR BRPI0014972-1A patent/BR0014972B1/pt not_active IP Right Cessation
- 2000-10-17 HK HK03101868.4A patent/HK1049826B/zh not_active IP Right Cessation
- 2000-10-17 YU YU73004A patent/YU73004A/sh unknown
- 2000-10-17 AP AP2004003186A patent/AP2004003186A0/xx unknown
- 2000-10-17 MX MXPA02003229A patent/MXPA02003229A/es active IP Right Grant
- 2000-10-17 CN CNB008145644A patent/CN1165518C/zh not_active Expired - Fee Related
- 2000-10-17 OA OA1200200117A patent/OA12070A/en unknown
- 2000-10-17 JP JP2001531783A patent/JP3632191B2/ja not_active Expired - Fee Related
- 2000-10-17 AT AT00972226T patent/ATE293590T1/de not_active IP Right Cessation
- 2000-10-17 US US10/130,023 patent/US6689906B1/en not_active Expired - Fee Related
- 2000-10-17 EA EA200200293A patent/EA005206B1/ru unknown
- 2000-10-17 TR TR2005/00221T patent/TR200500221T2/xx unknown
- 2000-10-17 EE EEP200200211A patent/EE200200211A/xx unknown
- 2000-10-17 EP EP04027485A patent/EP1506955B1/en not_active Expired - Lifetime
- 2000-10-17 SK SK523-2002A patent/SK5232002A3/sk unknown
- 2000-10-17 AU AU10920/01A patent/AU778871B2/en not_active Ceased
- 2000-10-17 AP APAP/P/2002/002517A patent/AP2002002517A0/en unknown
- 2000-10-18 PA PA20008505201A patent/PA8505201A1/es unknown
- 2000-10-18 MY MYPI20004896A patent/MY127678A/en unknown
- 2000-10-19 GT GT200000183A patent/GT200000183A/es unknown
- 2000-10-19 AR ARP000105497A patent/AR026087A1/es unknown
- 2000-10-19 CO CO00079741A patent/CO5280060A1/es not_active Application Discontinuation
- 2000-10-19 DO DO2000000083A patent/DOP2000000083A/es unknown
- 2000-10-19 GT GT200000183AK patent/GT200000183AA/es unknown
- 2000-10-19 PE PE2000001116A patent/PE20010740A1/es not_active Application Discontinuation
- 2000-10-20 TW TW093125953A patent/TW200505824A/zh unknown
- 2000-10-20 TW TW089122115A patent/TWI225855B/zh not_active IP Right Cessation
-
2002
- 2002-03-28 ZA ZA200202543A patent/ZA200202543B/xx unknown
- 2002-04-15 IL IL149143A patent/IL149143A/en unknown
- 2002-04-16 CU CU78A patent/CU23112A3/es unknown
- 2002-04-16 NO NO20021780A patent/NO20021780L/no not_active Application Discontinuation
- 2002-04-17 IS IS6348A patent/IS6348A/is unknown
- 2002-04-18 CR CR6620A patent/CR6620A/es not_active Application Discontinuation
- 2002-05-10 MA MA26634A patent/MA26842A1/fr unknown
- 2002-05-20 BG BG106719A patent/BG106719A/bg unknown
- 2002-05-20 BG BG108860A patent/BG108860A/en unknown
-
2004
- 2004-01-21 US US10/762,026 patent/US6835751B2/en not_active Expired - Fee Related
- 2004-07-28 EC EC2004005393A patent/ECSP045393A/es unknown
- 2004-08-17 AR ARP040102937A patent/AR045456A2/es unknown
- 2004-09-01 NO NO20043663A patent/NO20043663L/no not_active Application Discontinuation
- 2004-09-14 JP JP2004266488A patent/JP3744928B2/ja not_active Expired - Fee Related
- 2004-10-08 IS IS7497A patent/IS7497A/is unknown
-
2005
- 2005-03-23 AU AU2005201268A patent/AU2005201268A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20043297B (en) | Bicyclic Amino Acids as Pharmaceutical Agents | |
| GEP20094817B (en) | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | |
| MX9806069A (es) | Novedosos amino acidos ciclicos substituidos como agentes farmaceuticos. | |
| ZA97991B (en) | Novel cyclic amino acids as pharmaceutical agents. | |
| NZ503963A (en) | 1-substituted-1-aminomethyl-cycloalkane derivatives, or gabapentin analogues, preparation and use in the treatment of neurological disorders | |
| CA2322558A1 (en) | Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel | |
| HRP970560B1 (en) | Substituted gamma aminobutyric acids as pharmaceutical agents | |
| ES2169848T3 (es) | Nuevos aminoacidos ciclicos coronados como agentes farmaceuticos. | |
| AP1397A (en) | Mono-and disubstituted 3-propyl gamma-aminobutyric acids. | |
| AU4673300A (en) | Amino heterocycles useful as pharmaceutical agents | |
| BR0010961A (pt) | Composto, composição farmacêutica, e, métodos para tratar epilepsia, ataques de tontura, hipocinésia, e distúrbios cranianos, distúrbios neurodegenerativos, depressão, ansiedade, pânico, dor, distúrbios neuropatológicos e distúrbios do sono | |
| CA2245647A1 (en) | Novel bridged cyclic amino acids as pharmaceutical agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |